The role of GLP-1 receptor agonists in the obesity pandemic
OA Version
Citation
Abstract
Overweight (BMI greater than 25 kg/m^2) and obese (BMI greater than 30 kg/m^2), along with their comorbidities, affect an increasing proportion of the world. Obesity and its pathologies not only decrease lifespan but also decrease quality of life. In the last century, access to food, particularly unhealthy food, has gone well beyond what would be found in humanity's ancient environment. In a society where the environment has changed rapidly, in dissent with human evolution, the question of how to treat the obesity pandemic is pressing. This paper will discuss how the United States reached approximately 70% of adults being overweight and obese, evaluate the attempted pharmacological interventions, and discover what the newest pharmacological advancement, GLP-1 receptor agonists, has to teach scientists about obesity pathology and intervention.
Description
2024